[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100578840":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":41,"centralContacts":45,"locations":27,"responsibleParty":55,"collaborators":59,"id":70,"slug":71,"hasResults":72,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":27,"eligibilityCriteria":75,"healthyVolunteers":72,"sex":76,"minAge":77,"maxAge":77,"enrollmentInfo":78,"targetDuration":27,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":92,"whyStopped":27,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":27},{"fullName":5,"class":6},"ETH Zurich","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"Iron treatment group","ACTIVE_COMPARATOR","daily multivitamin + daily iron syrup from age 6 to 10 months",[13,14,15,16],"Dietary Supplement: Iron syrup","Dietary Supplement: Multivitamin syrup","Biological: R21-Matrix\u002FM Vaccine (malaria vaccine)","Biological: Measles-Rubella vaccine",{"label":18,"type":6,"description":19,"interventionNames":20},"Control group","daily multivitamin syrup from age 6 to 10 months",[14,15,16],[22,28,32,37],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DIETARY_SUPPLEMENT","Iron syrup","Iron syrup administered daily from 6 to 10 months of age.",[9],null,{"type":23,"name":29,"description":30,"armGroupLabels":31,"otherNames":27},"Multivitamin syrup","Multivitamin syrup administered daily from 6 to 10 months of age.",[18,9],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":27},"BIOLOGICAL","R21-Matrix\u002FM Vaccine (malaria vaccine)","R21-Matrix\u002FM vaccine administered in 3 doses at 7, 8 and 9 months of age.",[18,9],{"type":33,"name":38,"description":39,"armGroupLabels":40,"otherNames":27},"Measles-Rubella vaccine","Measles-Rubella vaccine administered at 9 months of age.",[18,9],[42],{"name":43,"affiliation":5,"role":44},"Nicole Stoffel, PhD","PRINCIPAL_INVESTIGATOR",[46,51],{"name":43,"role":47,"phone":48,"phoneExt":49,"email":50},"CONTACT","044 632 83 93","+41","nicole.stoffel@hest.ethz.ch",{"name":52,"role":47,"phone":53,"phoneExt":49,"email":54},"Giulia Pironaci, MSc","0799343770","giulia.pironaci@rdm.ox.ac.uk",{"type":56,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":27,"oldOrganization":27},"SPONSOR_INVESTIGATOR","Nicole Stoffel","Prof.",[60,62,65,67],{"name":61,"class":6},"Jomo Kenyatta University of Agriculture and Technology",{"name":63,"class":64},"University of Oxford - Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences","UNKNOWN",{"name":66,"class":64},"Faculty of Medical Sciences, Radboud University of Medical Center",{"name":68,"class":69},"National Institute for Public Health and the Environment (RIVM)","OTHER_GOV","100578840","the-effects-of-iron-treatment-on-malaria-and-measles-vaccine-response-in-kenyan-infants-with-iron-deficiency-100578840",false,"NCT06816524","The Effects of Iron Treatment on Malaria and Measles Vaccine Response in Kenyan Infants With Iron Deficiency","Inclusion Criteria:\n\n* Subject's caregiver is willing and able to give informed consent\n* Male or Female, 6 months (+\u002F- 2 weeks) of age\n* Mother at least ≥15 years of age\n* Iron deficient (erythrocyte zinc protoporphyrin (ZnPP) \\>61 μmol\u002Fmol heme)\n* With or without anemia (anemia defined by Hb \\\u003C110 g\u002FL)\n\nExclusion Criteria:\n\n* Severely anemic (Hb \\\u003C70 g\u002FL)\n* Malaria vaccination prior to enrollment\n* Medical condition that precludes study involvement\n* Iron supplementation 2 weeks before enrollment\n* Acute or chronic infection (e.g. HIV)\n* Wasted (length for height z score of ≥-2) or underweight (weight for age z score ≥-2).","ALL","6 Months",{"count":79,"type":80},324,"ESTIMATED","INTERVENTIONAL",[83],"NA","Malaria and iron deficiency cause a significant burden of disease in Africa. Iron deficiency (ID) might affect immune responses to vaccination.\n\nIn this double-blind randomized controlled trial, we aim to assess: (1) whether ID impairs R21\u002FMatrix-M and measles (MR) vaccine response, (2) whether iron treatment at time of vaccination improves vaccine response.",[86],"Iron Deficiencies",[88,89,90,91],"Iron deficiency","Vaccine immunogenicity","Malaria","Measles","NOT_YET_RECRUITING","2025-12-19",{"date":95,"type":96},"2025-12-26","ACTUAL",{"date":98,"type":80},"2026-01-05",{"date":100,"type":80},"2028-04-30",{"name":57,"class":6}]